Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment

European Journal of Neurology

Volumn 20, Issue 10, 2013, Pages 1390-1397

  Malhotra, S ^a   Morcillo Suarez C ^b,c   Nurtdinov, R ^a   Rio, J ^a   Sarro, E ^d   Moreno, M ^a   Castillo J ^a   Navarro, A ^b,e   Montalban, X ^a   Comabella, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTE OF EVOLUTIONARY BIOLOGY CSIC UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d VHIR CIBBIM Nanomedicina ^*  (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Genetic susceptibility; Interferon ; Multiple sclerosis; Response to treatment; USP18 polymorphisms

Indexed keywords

BETA INTERFERON; HEAT SHOCK TRANSCRIPTION FACTOR 1; PEPTIDASE; STAT PROTEIN; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR NFAT; UBIQUITIN; UBIQUITIN SPECIFIC PEPTIDASE 18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING SITE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE RISK; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

GENETIC SUSCEPTIBILITY; INTERFERON-Β; MULTIPLE SCLEROSIS; RESPONSE TO TREATMENT; USP18 POLYMORPHISMS;

ADULT; CYTOKINES; DRUG RESISTANCE; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TREATMENT OUTCOME; UBIQUITINS;

EID: 84883750369     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12193     Document Type: Article

References (25)

1. Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 2011; 31: 119-130.
2. Sarasin-Filipowicz M, Wang X, Yan M, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009; 29: 4841-4851.
3. Honke N, Shaabani N, Cadeddu G, et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 2011; 13: 51-57.
4. Malakhova OA, Kim KI, Luo JK, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25: 2358-2367.
5. Malhotra S, Bustamante MF, Pérez-Miralles F, et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS ONE 2011; 6: e23634.
6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
8. Río J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
10. Matys V, Kel-Margoulis OV, Fricke E, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006; 34: D108-D110.
11. Morcillo-Suarez C, Alegre J, Sangros R, et al. SNP Analysis to Results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. Bioinformatics 2008; 24: 1643-1644.
12. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
13. Burkart C, Fan JB, Zhang DE. Two independent mechanisms promote expression of an N-terminal truncated USP18 isoform with higher DeISGylation activity in the nucleus. J Biol Chem 2012; 287: 4883-4893.
14. Malakhova OA, Yan M, Malakhov MP, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 2003; 17: 455-460.
15. Zou W, Kim JH, Handidu A, et al. Microarray analysis reveals that type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophages. Biochem Biophys Res Commun 2007; 356: 193-199.
16. Santin I, Moore F, Grieco FA, et al. USP18 is a key regulator of the interferon-driven gene network modulating pancreatic beta cell inflammation and apoptosis. Cell Death Dis 2012; 3: e419.
17. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009; 132: 3353-3365.
18. Bustamante MF, Fissolo N, Río J, et al. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis. Ann Neurol 2011; 70: 634-645.
19. Duex JE, Comeau L, Sorkin A, et al. Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 2011; 286: 25377-25386.
20. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
21. Sofo V, Salmeri FM, Di Bella P, et al. Short communication: impairment of membrane markers on peripheral blood mononuclear cells and imbalance of cytokine secretion in the pathogenesis of multiple sclerosis active phases. J Interferon Cytokine Res 2005; 25: 661-665.
22. Achiron A, Feldman A, Mandel M, et al. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 2007; 1107: 155-167.
23. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
24. Comabella M, Craig DW, Camiña-Tato M, et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500, 000 single nucleotide polymorphisms. PLoS ONE 2008; 3: e3490.
25. Malhotra S, Morcillo-Suárez C, Brassat D, et al. IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis. J Neuroimmunol 2011; 239: 101-104.